With a career spanning venture investing, company building, strategy consulting and basic research in the life sciences, Jan joined Apollo to focus on Company Creation, one of the cornerstones of Apollo’s investment thesis. Prior to joining Apollo. Jan was a heading commercial activity at the Merck KGaA Innovation Center in Darmstadt, looking to operationalize market-related topics of projects from within the Merck Group. Before that he was a Managing Director with EMBL Ventures, a Seed and Early-stage VC that was working closely with EMBL, Europe’s flagship laboratory in the life sciences. Notable companies that Jan has been involved with on board level and as investor include Endoart (acquired by Allergan), ViraTherapeutics (acquired by Boehringer Ingelheim), Lipid Therapeutics (licensing to Nestlé Health Science), Apellis Pharmaceuticals and Arsanis Bioscience (both IPO at NASDAQ). Jan is trained as a biochemist with an MSc from Tübingen University, Germany, and a PhD in molecular genetics from the University of Cambridge, UK. He additionally obtained a dual MBA degree from ESSEC (Paris) and Mannheim University (Germany) and is a Class 11 Kauffman Fellow.